Substance / Medication

Troglitazone

Overview

Active Ingredient
troglitazone
RxNorm CUI
72610

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

903 trials linked to this intervention

903
Total Trials
103
Recruiting
282
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Lord J M, Flight I H K, Norman R J · Cochrane Database Syst Rev · 2003
PMID: 12917943Meta-Analysis
Sequence variation in PPARG may underlie differential response to troglitazone.
Wolford Johanna K, Yeatts Kimberly A, Dhanjal Sharanjeet K et al. · Diabetes · 2005
PMID: 16249460RCTFull text (PMC)
The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease.
Mohideen Pharis, Bornemann Michael, Sugihara Jared et al. · Endocrine · 2005
PMID: 16388091RCT
Effect of troglitazone on serum gamma-glutamyltransferase activity and plasma t-PA/PAI-1 complex in type 2 diabetic patients.
Koh Hideki, Akiyama Yoshitaka, Yui Katsumasa · Arzneimittelforschung · 2006
PMID: 16724515Trial
Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
Buras Jon, Reenstra Wende R, Orlow Daniel et al. · Obes Res · 2005
PMID: 16076985Trial
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Knowler William C, Hamman Richard F, Edelstein Sharon L et al. · Diabetes · 2005
PMID: 15793255TrialFull text (PMC)
Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Levin Klaus, Hother-Nielsen Ole, Henriksen Jan Erik et al. · Diabetes Care · 2004
PMID: 14693981Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Troglitazone (substance)
SNOMED CT
386967007
UMLS CUI
C0245514
RxNorm CUI
72610

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
903
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.